Testing a nerve target in Parkinson’s disease
Part of Brain & nervous system clinical trials.
This trial is studying the “superior cervical ganglion” as a possible treatment approach for Parkinson’s disease. It may help people whose symptoms are truly caused by Parkinson’s, not by another condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Parkinson’s disease, based on standard specialist diagnostic rules
- Your brain/nervous system exam should not clearly show cerebellum-type problems (balance/coordination or certain eye movement issues)
- You should not have certain specific eye movement problems related to vertical gaze control
- You should not have early frontotemporal dementia or primary progressive aphasia (within the first 5 years)
- Parkinson-like symptoms should not be limited to the lower legs for more than 3 years
- You must not have been likely misdiagnosed—other causes of “parkinsonism” should not explain your symptoms more than Parkinson’s
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called NouvNeu001 for Parkinson's disease. It involves a one-time brain surgery to deliver the treatment, and researchers will check if it's safe and helps with symptoms.
This trial tests whether targeted electrical stimulation of the spinal cord can improve movement and reduce symptoms in people with Parkinson's disease. It is for those who have had Parkinson's for at least five years, are still responding to levodopa but have motor fluctuations.
This trial tests a new treatment made from your own cells to replace damaged brain cells, aiming to improve movement and reduce symptoms. It's for people who have had Parkinson's for at least 4 years and respond well to levodopa.
This study compares two areas of the brain (subthalamic nucleus and globus pallidus interna) for stimulation using a new non-invasive technique called tTIS. The goal is to see which area works better to improve Parkinson's symptoms.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.